Tocainide

Tocainide

Systematic (IUPAC) name
N-(2,6-dimethylphenyl)alaninamide
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a601248
Pregnancy cat.	?
Legal status	?
Pharmacokinetic data
Bioavailability	0.9-1 (oral)
Protein binding	10-20%
Metabolism	glucuronidation (primary)
Half-life	9-14 R, 13-20 S
Excretion	30-50% urine (unchanged)
Identifiers
CAS number	41708-72-9 Y
ATC code	C01BB03
PubChem	CID 38945
DrugBank	APRD01266
ChemSpider	35632 Y
UNII	27DXO59SAN Y
KEGG	D06172 Y
ChEBI	CHEBI:9611 Y
ChEMBL	CHEMBL1762 Y
Chemical data
Formula	C11H16N2O
Mol. mass	192.258 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C11H16N2O/c1-7-5-4-6-8(2)10(7)13-11(14)9(3)12/h4-6,9H,12H2,1-3H3,(H,13,14) Y Key:BUJAGSGYPOAWEI-UHFFFAOYSA-N Y
N(what is this?)  (verify)

Tocainide (Tonocard) is a class Ib antiarrhythmic agent. It is no longer sold in the United States.

Quick look at the Pharmacokinetics

Tocainide is a lidocaine analog, that does not have significant 1st pass metabolism. It is found in two enantiomers. The R isomer is 4x as potent as the S. Oral bioavailability is 0.9-1.0. In the blood tocainide is 10-20% protein bound. The Volume of distribution is 2.5-3.5 L/kg. 30-50% is excreted unchanged in the urine. The more active R-isomer is cleared faster in anephric patients or those with severe renal dysfunction. The main metabolite is the glucuronidated tocainide carbamic acid. The glucuronosyl transferase is apparently induced by rifampin. Weak inhibition of Cyp1A2 leads to a mild theophylline interaction. (Not verbatim)

External links

• MedlinePlus DrugInfo medmaster-a685030

Burton ME. Applied Pharmacokinetics & Pharmacodynamics: Principles of Therapeutic Drug Monitoring. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.